Compare Agnico Eagle Mines Ltd (AEM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs BIO-TECHNE Corp — how do they compare? Agnico Eagle Mines Ltd trades at $145.49 (market cap $75.10B), while BIO-TECHNE Corp trades at $70.89 (market cap $11.00B). The key difference: Agnico Eagle Mines Ltd is far larger — about 6.8× BIO-TECHNE Corp's market cap, and Agnico Eagle Mines Ltd pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| AEM | TECH | |
|---|---|---|
Market Cap | $75.10B | $11.00B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $71.38 |
52-Week Low | $116.14 | $43.31 |
Enterprise Value | $72.30B | $11.08B |
Dividend Yield | 1.2% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
